India’s drug regulator has accelerated pharma innovation by cutting approval timelines by more than half. Clinical trial approvals will now take about 120-135 days, while marketing authorisations are cleared in under 150 days. The reforms also remove certain pre-clinical approval requirements, aiming to strengthen ease of doing business and speed product delivery.
India’s appetite for weight-loss injectables like Ozempic and Mounjaro is rising fast, with consumers seeking gradual weight reduction. But healthcare professionals are warning that the current regulatory and marketing environment is not keeping pace, increasing the risk of misuse and improper promotion. Calls are growing for stronger oversight to protect patients.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
